Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-10), Q-linea AB's 12-1 Month Momentum % is N/A%.
The industry rank for Q-linea AB's 12-1 Month Momentum % or its related term are showing as below:
CHIX:QLINEs's 12-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -16.93 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Q-linea AB (CHIX:QLINEs) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Q-linea AB 12-1 Month Momentum % Related Terms
CHIX:QLINES vs ABT, SYK, MDT: 12-1 Month Momentum % Comparison
For the Medical Devices subindustry, Q-linea AB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB 12-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Q-linea AB's 12-1 Month Momentum % falls into.
Q-linea AB (CHIX:QLINEs) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (CHIX:QLINES) has a 12-1 Month Momentum % of N/A% as of Aug. 10, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Q-linea AB and its competitors. According to the industry distribution chart, Q-linea AB ranks #765 out of 828 companies in the Medical Devices & Instruments industry, placing it in the top 92.4%.
Is Q-linea AB's 12-1 Month Momentum % too high?
Q-linea AB's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Q-linea AB ranks #765 out of 828 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-linea AB has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's 12-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #765 out of 828 companies for 12-1 Month Momentum %. This places Q-linea AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Q-linea AB and its competitors. Q-linea AB's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current 12-1 Month Momentum % of N/A%. The stock's GF Value™ is kr1,746.20, compared to a current price of kr1,610.00 — trading 7.8% below its estimated fair value. The current 12-1 Month Momentum % is N/A%. Q-linea AB's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current 12-1 Month Momentum % is N/A% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 7.8% below its estimated GF Value™ of kr1,746.20.
Key valuation signals for CHIX:QLINES:
12-1 Month Momentum %: N/A%
GF Value™: kr1,746.20 vs. price of kr1,610.00 (7.8% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
61GF Score
Get the complete analysis for CHIX:QLINES
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
